Shares of Nanobiotix (NBTX), a biotechnology company, soared 6.51% in after-hours trading on Wednesday, following a bullish analyst report earlier in the day. The stock's upward movement came as investors reacted positively to the reiterated confidence from a prominent Wall Street firm.

Leerink Partners analyst Jonathan Chang maintained a Buy rating on Nanobiotix and set an ambitious price target of $24.00. This vote of confidence from a respected analyst appears to have sparked renewed interest in the stock, leading to increased buying activity after the regular trading session had concluded.

The $24.00 price target suggests significant upside potential for Nanobiotix shares, which likely contributed to the enthusiasm among investors. While the specific reasons behind the analyst's optimistic outlook were not detailed in the available information, such ratings are often based on a company's financial health, growth prospects, and potential breakthroughs in its field of expertise. As a biotechnology firm, Nanobiotix's stock performance can be particularly sensitive to analyst opinions and potential advancements in its research and development efforts.